European Medicines Pricing and Reimbursement
Regular price
€49.99
14 days return policy
Shipping & Delivery
A01=Jorge Mestre-Ferrandiz
A01=Martina Garau
A01=Michael Loh
AIFA
ASMR
Author_Jorge Mestre-Ferrandiz
Author_Martina Garau
Author_Michael Loh
Category=KC
Category=KND
comparative health policy
cost utility analysis
Costa-i-Font Joan
Danzon Patricia
DDD
DRG Cost
DRG System
drug reimbursement models
Economic Evaluation Studies
eq_bestseller
eq_business-finance-law
eq_isMigrated=1
eq_isMigrated=2
eq_nobargain
eq_non-fiction
European pharmaceutical pricing strategies
expenditure
funds
Garattini Livio
Garau Martina
German Healthcare System
Graf von der Schulenburg J-Matthias
health economics
Health Technology Assessment
Health Technology Assessment Studies
healthcare
HTA
IMS Data
Incremental Cost Effectiveness Ratio
Joint Federal Committee
Le Pen Claude
NHS Sale
NHS Spending
Nice Guidance
Parallel Trade
pharmaceutical
Pharmaceutical Expenditure
Pharmaceutical Policy
pharmaceutical regulation
Pharmaco Economic Studies
policy
price
Public Pharmaceutical Expenditure
public sector medicine funding
reference
Reference Price System
sickness
Sickness Funds
system
Total Pharmaceutical Expenditure
Towse Adrian
transparency
Transparency Commission
Product details
- ISBN 9781846191848
- Weight: 272g
- Dimensions: 305 x 152mm
- Publication Date: 30 Nov 2006
- Publisher: Taylor & Francis Ltd
- Publication City/Country: GB
- Product Form: Paperback
Secure
checkout
Fast Shipping
Easy returns
This book is published in association with the Office of Health Economics. This book is a vital, non-technical guide illuminating recent developments within the five major European pharmaceutical markets. It clearly explains pharmaceutical regulatory policies on pricing and reimbursement, and their effects. Each chapter gives an overview of the current market, including aims, effectiveness, local markets, frameworks and politics, and then offers predictions for the next decade. Pharmaceutical executives with interests in marketing, market access and pricing will find this guide invaluable, as will health economists, government advisors and public affairs consultants. Public policy makers in areas such as the Department of Health and The Treasury and senior health service managers in hospitals will find it enlightening. It is also highly relevant to policy shapers in academia and the media, and undergraduate and postgraduate students of health economics, health policy, pharmaceutical economics and healthcare management. "This book aims not only to understand and discuss the mix of regulatory measures introduced by national policy makers in order to achieve their goals, but also to ascertain how these policies have actually shaped and influenced the characteristics and functioning of national pharmaceutical markets. In particular, each author has provided an analysis of existing pricing and reimbursement arrangements operating in their own country and an outline of policy scenarios that might emerge in the next decade." - Martina Garau and Jorge Mestre-Ferrandiz, in the Introduction.
Martina Garau, Jorge Mestre-Ferrandiz, Michael Loh
